RESEARCH ARTICLE

Sonographic findings in coronavirus disease-19 associated liver damage

Jakob Spogis1, Florian Hagen1, Wolfgang M. Thaiss1,2, Tatjana Hoffmann3, Nisar Malek3, Konstantin Nikolaou1, Christoph P. Berg1, Stephan Singer4, Hans Bösmüller4, Florian Kreth3, Sascha Kaufmann1*

1 Department of Diagnostic and Interventional Radiology, Eberhard-Karls-University, Tübingen, Germany, 2 Department of Nuclear Medicine, University Hospital Ulm, Ulm, Germany, 3 Internal Medicine, Eberhard-Karls-University, Tübingen, Germany, 4 Pathology, Eberhard-Karls-University, Tübingen, Germany

* Sascha.kaufmann@med.uni-tuebingen.de

Abstract

Purpose

This study was conducted to evaluate the role of liver sonography in patients with coronavirus disease 2019 (COVID-19) and elevated liver enzymes.

Materials and methods

In this retrospective study, patients tested positive for SARS-CoV-2 in our emergency ward between January 01 and April 24, 2020 and elevated liver enzymes were included (Cohort 1). Additionally, the local radiology information system was screened for sonographies in COVID-19 patients at the intensive care unit in the same period (Cohort 2). Liver sonographies and histologic specimen were reviewed and suspicious findings recorded. Medical records were reviewed for clinical data. Ultrasound findings and clinical data were correlated with severity of liver enzyme elevation.

Results

Cohort 1: 126 patients were evaluated, of which 47 (37.3%) had elevated liver enzymes. Severity of liver enzyme elevation was associated with death (p<0.001). 8 patients (6.3%) had suspicious ultrasound findings, including signs of acute hepatitis (n = 5, e.g. thickening of gall bladder wall, hepatomegaly, decreased echogenicity of liver parenchyma) and vascular complications (n = 4). Cohort 2: 39 patients were evaluated, of which 14 are also included in Cohort 1. 19 patients (48.7%) had suspicious ultrasound findings, of which 13 patients had signs of acute hepatitis and 6 had vascular complications. Pathology was performed in 6 patients. Predominant findings were severe cholestasis and macrophage activation.

Conclusion

For most hospitalized COVID-19 patients, elevated liver enzymes cause little concern as they are only mild to moderate. However, in severely ill patients bedside sonography is a powerful tool to reveal different patterns of vascular, cholestatic or inflammatory
complications in the liver, which are associated with high mortality. In addition, macrophage activation as histopathologic correlate for a hyperinflammatory syndrome seems to be a frequent complication in COVID-19.

Introduction

In December 2019, the novel coronavirus (SARS-CoV-2) broke out in Wuhan, China. The associated disease, Coronavirus Disease 2019 (COVID-19), is typically characterized by the symptoms of a viral pneumonia, which may evolve to respiratory failure. With ongoing worldwide spread, more information about the incidence of elevated liver enzymes during the infection is gained. Increased AST and ALT was found in 21 and 22% of patients respectively [1], especially in severely ill patients. Nevertheless clinically significant acute liver damage seems to remain rare [2]. More often, the lungs, heart and kidneys are harmed in multiorgan failure [3].

The exact mechanism of liver damage in COVID-19 patients is unclear. In a biopsy specimen of a deceased patient with travel history to Wuhan, moderate microvascular steatosis and mild lobular and portal activation was seen, caused either by the infection or by drug toxicity [4]. Possible mechanisms of liver injury are: (a) Immune mediated damage due to severe inflammatory response, (b) direct cytotoxicity due to active viral replication, (c) anoxia in respiratory failure, (d) drug induced liver injury, or (e) reactivation of pre-existing liver disease [5].

Despite its high prevalence, no systematic investigation of the imaging workup of elevated transaminases was performed so far. This study aims to clarify the role of sonography because of its high usability in critically ill patients and intensive care units (ICU).

Material and methods

Institutional board approval

This retrospective single-center study was approved by the institutional ethics committee of the University of Tuebingen under the approval number 543/2020BO. Written informed consent was waived in order to obtain a representative study population in the retrospective analysis. The study was conducted in accordance with the current version of the Declaration of Helsinki.

Patients

Two cohorts with partial overlap were examined in this retrospective study:

- **Cohort 1:** Patients who were tested positive for SARS-CoV-2 in the emergency department of our hospital between January 01 and April 24, 2020 were screened for elevated liver enzymes. Patients were assigned to three groups according to the highest measured value of alanine aminotransferase (ALT):

1. normal ALT,
2. mild to moderate elevation defined as ALT < 10 times upper normal limit (UNL),
3. severe elevation, defined as ALT > 10 times UNL.

Patients of group 2 and 3 were followed with regard to documented sonographies, MRI and histologic specimen of the liver. The maximum values of ALT, aspartate aminotransferase
(AST), gamma-glutamyl transferase (GGT), alkaline phosphatase (ALP) and total bilirubin were recorded.

**Cohort 2**: In a second analysis, the local radiology information system (RIS) was screened for sonographies performed at the ICU of our hospital in the same period as Cohort 1 as diagnostic workup for elevated liver enzymes in COVID-19 patients. All patients had positive test for SARS-CoV-2 in our institution. Patients were assigned to the above-mentioned groups and followed for histologic specimen and MRI for comparison with ultrasound findings. Maximum values of the same laboratory results as Cohort 1 were recorded.

**Sonography**

Every patient admitted to our hospital with the diagnosis of COVID-19 and elevated liver enzymes received abdominal sonography during the inpatient treatment. Sonographies at ICU were performed using a Philips HD 11 XE or CX50 (Philips medical systems, Hamburg, Germany) with documentation in the local Picture Archiving and Communication System (PACS). Radiologists with a minimum of 3 years of clinical ultrasound experience performed the examinations at bedside. During the examination the physician wore a disposable cap, a FFP2-mask, protective suit and disposable latex gloves. None of the physicians got infected during the study. The liver and gall bladder were examined transcostally and subcostally with the patient in supine position.

Patients at the infection ward received sonography by the ward using a Philips Sparq (Philips medical systems, Hamburg, Germany).

**Image analysis**

The ultrasound images were reevaluated by two physicians with 3 and 14 years of experience in clinical ultrasound. Images were analyzed with regard to signs of hepatomegaly, echogenicity of the liver compared with the kidneys and the intrahepatic bile ducts (also known as starry sky appearance in case of decreased echogenicity), cholestasis, flow signal of the portal vein, hepatic artery and veins, thickening of the gallbladder wall, cholecystolithiasis and ascites. In case of repeated examination the most suspicious findings were recorded.

**Statistical analysis**

JMP 14.2.0 (SAS Institute Inc.; Cary, NC) was used for statistical analysis. Measurement data were presented as mean +/- standard deviation and analyzed using t-test, chi-square test and Fisher’s exact test. After verification of Gaussian distribution of every parameter by the Shapiro-Wilk test, we opted for a unpaired t-test. A p-value of less than 0.05 was considered statistically significant.

**Results**

**Clinical data**

The flowchart of research subject selection and follow-up is shown in Fig 1 for cohort 1 and in Fig 2 for cohort 2. 14 patients are included in both cohorts. No patient had previously known liver disease such as viral hepatitis, liver cirrhosis or history of alcohol abuse.

**Cohort 1**: 126 patients were tested positive for SARS-CoV-19 in the emergency department (63 male and 63 female) with no significant difference in age between male and female patients (p = 0.15). 88 (69.8%, 88/126) received inpatient treatment, 36 (28.6%, 36/126) were admitted to ICU. 39 (31.0%, 39/126) were assigned to group 2 (mild to moderate elevation of liver enzymes, 7 (5.6%, 5/126) were assigned to group 3. In group 2, 23 (59.0%, 23/39) were male, in
group 3, 6 (85.7%, 6/7) were male. 17 (13.5%, 17/126) patients died, of which 1 (1.3%, 1/80) in group 1, 11 (28.2%, 11/39) in group 2 and 5 (71.4%, 5/7) in group 3 (χ² (2) = 37.64, p < 0.001).

Cohort 2: 39 patients at ICU received sonography of the liver, of which 14 are also included in cohort 1. 31 (79.5%, 31/39) patients were assigned to group 2 (mild to moderate elevation of transaminases), of which 13 (42%, 13/31) died. 8 (20.5%, 8/39) were assigned to group 3, all of which died (χ² (1) = 7.77, p = 0.005).

Patient characteristics and laboratory results of both cohorts are shown in Table 1.

Sonography findings

Cohort 1: In group 2, 3 (7.7%, 3/39) patients had positive sonography. All of them showed signs of acute hepatitis (thickening of gall bladder wall, hepatomegaly, decreased echogenicity of the liver, Fig 3). In one patient, additionally no Doppler signal was found in the hepatic artery (Fig 4). In group 3, 5 (71.4%, 5/7) had positive sonography. Two patients had signs of acute hepatitis, three showed signs of a vascular complication: two had no detectible Doppler signal of the hepatic artery, one showed inhomogeneous liver parenchyma as a sign of tissue necrosis (Fig 5). Positive sonography was not significantly associated with severity of liver enzyme elevation (p = 0.07) or death (p = 0.2).

Cohort 2: 12 (38.7%, 12/31) patients of group 2 had positive sonography (10x signs of acute hepatitis, one with inhomogeneous liver tissue, one with no detectable Doppler signal of the hepatic artery), of which two are also included in cohort 1. In group 3, 7 (87.5%, 7/8) had positive sonography (3x signs of acute hepatitis, 4x signs of vascular complication), of which four are also included in cohort 1. Positive sonography was associated with severity of liver enzyme elevation (p = 0.018) and death (p = 0.006).
Sonographic findings are summarized for both cohorts in Table 2.

**Histology and other imaging findings**

Five patients with positive sonography received an autopsy. The predominant finding was severe cholestasis, found in four patients (Fig 6). Macrophage activation was found in three patients. Table 3 summarizes the histologic findings and their correlate in sonography.

One patient of group 3 with negative sonography (Fig 7A) received MRI of the liver, where irregular bile ducts were detected and interpreted as secondary sclerosing cholangitis (SSC, Fig 7B). Liver specimen revealed endothelialitis and inflammatory changes of bile ducts similar to rejection reaction, not typical for SSC though (Fig 7C and 7D).

**Discussion**

COVID-19 is a highly contagious disease with extensive influence on public health. This study presents a representative patient cohort of a university hospital during the first outbreak of Corona Virus in Germany (Cohort 1) and additionally a non-representative patient cohort at the ICU (Cohort 2). In cohort 1, 37% of confirmed COVID-19 cases developed elevated liver enzymes, 83% of them only mildly. In previous studies, liver enzymes were elevated in 22% up to 53% of patients [1, 6, 7]. Huang et al. described elevation of AST in 62% of patients in the ICU compared to 25% of patients who did not require treatment in the ICU [8]. In our study, we show comparable results: Only one patient (1 / 80 = 1.3%) without elevated liver enzymes required treatment in the ICU, but 71.8% of those with mildly and all of those with severe
elevation of liver enzymes. Whereas COVID-19 affects both men and women equally—exact 50% of the positively tested patients in cohort 1 were men and women—elevated liver enzymes seem to be more frequent in men, especially severe elevation. Furthermore, we see a significant

### Table 1. Summary of patient characteristics and laboratory results.

|                        | Cohort 1 (N = 126) | Cohort 2 (N = 39) *** |
|------------------------|--------------------|-----------------------|
|                        | Group 1            | Group 2               | Group 3               |
|                        | no elevation       | ALT < 10x UNL         | ALT > 10x UNL         |
| N (% of total cohort)  | 80 (63.5)          | 39 (31.0)             | 7 (5.6)               |
| Male                   | 34 (42.5)          | 23 (59.0)             | 6 (85.7)              |
| Female                 | 46 (57.5)          | 16 (41.0)             | 1 (14.3)              |
| Age (Mean/SD)          | 60/18              | 77/9                  | 68/14                 |
| Inpatient treatment    | 42 (52.5)          | 39 (100)              | 7 (100)               |
| ICU treatment          | 1 (1.3)            | 28 (71.8)             | 7 (100)               |
| Death                  | 1 (1.3)            | 11 (28.2)             | 5 (71.4)              |
| Positive sonography    | 3 (7.7)            | 5 (71.4)              | 12 (38.7)             |
| Max. lab parameter (Mean/SD): |        |                      |                      |
| AST                    | "                   | 191/140               | 3302/2975             |
| ALT                    | "                   | 131/73                | 1254/741              |
| ALP                    | "                   | 208/167               | 656/385               |
| GGT                    | "                   | 329/394               | 1187/928              |
| Total Bilirubin        | "                   | 3.0/4.9               | 7.5/7.9               |

ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase; ALP, alkaline phosphatase; UNL, upper normal limit.

* One patient only.

** Parameters in normal range or not measured.

*** 14 patients are also part of cohort 1 (10 in group 2, 4 in group 3).

https://doi.org/10.1371/journal.pone.0244781.t001

Fig 3. Signs of acute hepatitis. (A) Pronounced thickening of the gallbladder wall, filled with sludge. This represents a typical sonographic finding in our study. (B) Indicated starry sky appearance of the liver with decreased echogenicity of liver parenchyma and pronounced bile ducts.

https://doi.org/10.1371/journal.pone.0244781.g003
increase in mortality between the different groups (group 1: 13.5%, group 2: 28.2%, group 3: 71.4%). It may be questioned if this is only due to the potential liver failure, since most of the deceased patients developed multi organ failure with the liver being only one part of it.

With respect to the ultrasound findings, most of the patients with only mildly elevated liver enzymes showed normal appearance of the liver (88.9%, 24 / 27) whereas 71.4% (5 / 7) of those with severely elevated liver enzymes had suspicious findings in ultrasound. We could identify two patterns of ultrasound findings:

![Fig 4. Vascular complications in the liver.](https://doi.org/10.1371/journal.pone.0244781.g004)

In this patient with severe deterioration of liver function only residual arterial Doppler signal could be found in the porta hepatis. The patient died the same day.

![Fig 5. Vascular complications in the liver.](https://doi.org/10.1371/journal.pone.0244781.g005)

In two cases, inhomogeneous echogenicity of the liver parenchyma was found. Autopsy confirmed the suspected diagnosis of liver necrosis in this case.
1. Most frequently and pronounced in group 2, we found a variable combination of distinct thickening of the gallbladder, decreased echogenicity of the liver—in part with starry sky appearance or swelling of the liver—and ascites. These findings are typical, but not specific for acute hepatitis [9–11].

2. As a second, less frequent pattern, we found vascular complications in the liver: In four cases the Doppler signal of the hepatic artery was strongly reduced or not detectible, suggesting hepatic artery thrombosis. Two patients showed geographic zones of hypoechoegenicity of liver parenchyma, a finding associated with hepatic infarction [12]. The second pattern was found especially in patients with severely elevated liver enzymes. All of these patients died the same day of the ultrasound examination.

These findings could be partially confirmed by autopsy. One case with sonographic signs of hepatitis showed granulocytic and histiocytic infiltrates in the liver. Necrosis was seen in both patients with signs of hepatitis and in one patient with geographic zones of hypoechoegenicity. In one case, obliteration of hepatic artery ramifications was detected. Unfortunately, the hepatic artery was not processed histologically, thus hepatic artery thrombosis could not be proven. As endothelialitis and thus arterial and venous thromboembolism are frequently observed in severe COVID-19 cases [13, 14], this may be the underlying reason of vascular complications in the liver.

Four out of five autopsied patients had massive cholestasis with the only sonographic correlate being sludge filled and wall thickened gall bladder but no dilation of bile ducts. Laboratory findings of cholestasis and biliary sludge are common findings in critically ill patients [15, 16] and thus not specific for COVID-19. In addition, the sonographic findings of gallbladder wall thickening and cholestasis are very unspecific and may also occur in conditions not associated with primary liver damage.

Most striking is, however, another histologic finding: Three out of five autopsies showed macrophage activation, the histopathologic correlate of secondary hemophagocytic lymphohistiocytosis (sHLH). Leading to multi organ failure due to excessive cytokine secretion, sHLH is a hyperinflammatory syndrome most frequently triggered by viral infections [17]. sHLH was described as a rare but severe complication also in COVID-19 patients in a late phase of the disease when Coronavirus-RNA is mostly not detectible anymore and systemic hyperinflammation mimics ongoing sepsis [18]. Frequently elevated d-dimer and the above

| Echogenicity of the liver | Group 2 | Group 3 |
|-------------------------|---------|---------|
| ALT < 10x UNL           | ALT > 10x UNL |
| Decreased               | 2       | 0       |
| Inhomogeneous           | 1       | 1       |
| Rounded liver angle / Hepatomegaly | 5 | 2 |
| Cholestasis             | 0       | 0       |
| Not detectible Hepatic artery | 1 | 3 |
| Thickened gallbladder wall | 10 | 4 |
| Gallstones              | 1       | 1       |
| Sludge                  | 7       | 2       |
| Ascites                 | 5       | 1       |

ALT, alanine aminotransferase; UNL, upper normal limit.

https://doi.org/10.1371/journal.pone.0244781.t002

PLOS ONE | https://doi.org/10.1371/journal.pone.0244781 February 19, 2021 8 / 12
mentioned thromboembolisms can also be explained in this context, as they are manifestations of defective procoagulant-anticoagulant balance [19]. Even though our patients didn’t meet all the criteria for sHLH, macrophage activation seems to be a frequently occurring complication in our institution—most likely due to our institution being a university hospital with many transferred patients from other hospitals.

As a summary of the above findings the 68-year-old patient described in Fig 7 may be interesting. Although he survived COVID-19, liver enzymes and especially GGT increased up to his discharge against medical advice. Unsuspicious in sonography, magnetic resonance cholangiopancreatography (MRCP) revealed irregular bile ducts and suspected diagnosis of SSC was made. Liver specimen finally depicted inflammatory changes of the endothelium, bile ducts and sinusoids not fitting to the suspected diagnosis of SSC but similar to changes seen in misguided immune response e.g. in cases of rejection reaction following liver transplant.

This study has limitations: First, as a retrospective single-center study its generalizability is limited and it underlies a selection bias. Furthermore, since 14 patients of Cohort 2 were also included in Cohort 1, statistical power of Cohort 2 may be affected when removing them from the analysis. Second, only for a few patients, histologic correlation was available. Third, we only took the highest measured value of ALT for group assignment. Thereby different courses of liver enzyme elevation remain unconsidered.

In conclusion, in most cases of COVID-19 elevated liver enzymes cause little concern, as they are only mild to moderate. In these cases ultrasound is usually unremarkable. In severe

Table 3. Summary of histologic findings with corresponding ultrasound findings.

| Sonography                   | Autopsy: Macroscopic                  | Histology                                                                 |
|-----------------------------|---------------------------------------|---------------------------------------------------------------------------|
| 1 Inhomogeneous liver echogenicity | Hepatomegaly, Gallbladder unsuspicious | Centroacinar necrosis; massive cholestasis; macrophage activation; no inflammation |
| 2 Hepatic artery not detectable; thickened gallbladder; ascites | Hepatomegaly; ascites                   | Normal structure; no necrosis; macrophage activation                       |
| 3 Hepatomegaly; thickened gallbladder | Gallbladder unsuspicious; liver greenish | Granulocytic and histiocytic infiltrates; endothelial damage; severe cholestasis; centroacinar necrosis |
| 4 Thickened gall bladder     | Hepatomegaly                           | Severe cholestasis; no necrosis                                           |
| 5 Gall bladder hydropic, sludge | Bloody ascites; no signs of liver dystrophy | Severe necrosis; pronounced cholestasis; macrophage activation            |
| 6 Unsuspicious MRI: Irregular bile ducts                     | Endothelialitis; bile duct-associated inflammation; similar to rejection reaction |

https://doi.org/10.1371/journal.pone.0244781.t003
cases though, especially at ICU, sonography can reveal vascular, cholestatic or inflammatory complications in the liver, which are associated with high mortality. It remains however unclear, whether these changes are caused by SARS-CoV-2 itself or by secondary hyperinflammation. Further studies are required to clarify the role of novel Coronavirus in acute liver damage.

Supporting information

S1 Data. Cohort 1.
(XLSX)

S2 Data. Cohort 2.
(XLSX)

Author Contributions

Conceptualization: Jakob Spogis, Konstantin Nikolaou, Sascha Kaufmann.

Data curation: Jakob Spogis, Stephan Singer, Hans Bösmüller, Florian Kreth.

Formal analysis: Jakob Spogis.

Funding acquisition: Konstantin Nikolaou.

Investigation: Jakob Spogis, Hans Bösmüller.
Methodology: Jakob Spogis, Florian Hagen, Christoph P. Berg, Sascha Kaufmann.

Project administration: Sascha Kaufmann.

Supervision: Nisar Malek, Konstantin Nikolaou, Sascha Kaufmann.

Writing – original draft: Jakob Spogis, Wolfgang M. Thaiss.

Writing – review & editing: Jakob Spogis, Florian Hagen, Wolfgang M. Thaiss, Tatjana Hoffmann, Nisar Malek, Konstantin Nikolaou, Christoph P. Berg, Hans Bömmler, Florian Kreth, Sascha Kaufmann.

References

1. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020; 382(18):1708–20. Epub 2020/02/29. https://doi.org/10.1056/NEJMoa2002032 PMID: 32109013; PubMed Central PMCID: PMC7092819.

2. Bangash MN, Patel J, Parekh D. COVID-19 and the liver: little cause for concern. Lancet Gastroenterol Hepatol. 2020; 5(6):529–30. Epub 2020/03/24. https://doi.org/10.1016/S2468-1253(20)30084-4 PMID: 32203680.

3. Li X, Wang L, Yan S, Yang F, Xiang L, Zhu J, et al. Clinical characteristics of 25 death cases with COVID-19: A retrospective review of medical records in a single medical center, Wuhan, China. Int J Infect Dis. 2020; 94:128–32. Epub 2020/04/07. https://doi.org/10.1016/j.ijid.2020.03.053 PMID: 32251805; PubMed Central PMCID: PMC7128884.

4. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8(4):420–2. Epub 2020/02/23. https://doi.org/10.1016/S2213-2600(20)30084-X PMID: 32085846; PubMed Central PMCID: PMC7164771.

5. Sun J, Aghemo A, Forner A, Valenti L. COVID-19 and liver disease. Liver Int. 2020; 40(6):1278–81. Epub 2020/04/07. https://doi.org/10.1111/liv.14470 PMID: 32251539.

6. Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020; 5(5):428–30. Epub 2020/03/08. https://doi.org/10.1016/S2468-1253(20)30057-1 PMID: 32145190; PubMed Central PMCID: PMC7129165.

7. Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis. 2020; 20(4):425–34. Epub 2020/02/28. https://doi.org/10.1016/S1473-3099(20)30086-4 PMID: 32105637; PubMed Central PMCID: PMC7159053.

8. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223):497–506. Epub 2020/01/28. https://doi.org/10.1016/S0140-6736(20)30183-5 PMID: 31986264; PubMed Central PMCID: PMC7159299.

9. Joshi G, Crawford KA, Hanna TN, Herr KD, Dahiya N, Menias CO. US of Right Upper Quadrant Pain in the Emergency Department: Diagnosing beyond Gallbladder and Biliary Disease. Radiographics. 2018; 38(3):766–93. Epub 2018/05/15. https://doi.org/10.1148/radiographics.2018170149 PMID: 29757718.

10. Heller MT, Tublin ME. The role of ultrasonography in the evaluation of diffuse liver disease. Radiol Clin North Am. 2014; 52(6):1163–75. Epub 2014/12/03. https://doi.org/10.1016/j.rcl.2014.07.013 PMID: 25444098.

11. Kurtz AB, Rubin CS, Cooper HS, Nisenbaum HL, Cole-Beuglet C, Medoff J, et al. Ultrasound findings in hepatitis. Radiology. 1980; 136(3):717–23. Epub 1980/09/01. https://doi.org/10.1148/radiology.136.3.7403553 PMID: 7403553.

12. Crossin JD, Muradali D, Wilson SR. US of liver transplants: normal and abnormal. Radiographics. 2003; 23(5):1093–114. Epub 2003/09/17. https://doi.org/10.1148/rg.235035031 PMID: 12975502.

13. Sardu C, Gambardella J, Morelli MB, Wang X, Marfella R, Santulli G. Hypertension, Thrombosis, Kidney Failure, and Diabetes: Is COVID-19 an Endothelial Disease? A Comprehensive Evaluation of Clinical and Basic Evidence. J Clin Med. 2020; 9(5). Epub 2020/05/15. https://doi.org/10.3390/jcm9051417 PMID: 32403217; PubMed Central PMCID: PMC7290769.

14. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020; 18(4):844–7. Epub 2020/02/20. https://doi.org/10.1111/jth.14768 PMID: 32073213; PubMed Central PMCID: PMC7166509.
15. Molenat F, Boussuges A, Valantin V, Sainty JM. Gallbladder abnormalities in medical ICU patients: an ultrasonographic study. Intensive Care Med. 1996; 22(4):356–8. Epub 1996/04/01. https://doi.org/10.1007/BF01700459 PMID: 8708175.

16. Murray FE, Stinchcombe SJ, Hawkey CJ. Development of biliary sludge in patients on intensive care unit: results of a prospective ultrasonographic study. Gut. 1992; 33(8):1123–5. Epub 1992/08/01. https://doi.org/10.1136/gut.33.8.1123 PMID: 1398240; PubMed Central PMCID: PMC1379455.

17. George MR. Hemophagocytic lymphohistiocytosis: review of etiologies and management. J Blood Med. 2014; 5:69–86. Epub 2014/06/27. https://doi.org/10.2147/JBM.S46255 PMID: 24966707; PubMed Central PMCID: PMC4062561.

18. Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal. J Heart Lung Transplant. 2020; 39(5):405–7. Epub 2020/05/05. https://doi.org/10.1016/j.healun.2020.03.012 PMID: 32362390; PubMed Central PMCID: PMC7118652.

19. Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med. 2020; 8(6):e46–e7. Epub 2020/05/01. https://doi.org/10.1016/S2213-2600(20)30216-2 PMID: 32353251; PubMed Central PMCID: PMC7185942.